1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Daan Gene Co., Ltd. Class A

Daan Gene Co., Ltd. Class A

SSZSE:002030
5.37
CNY
+0.03
(+0.56%)
-0.71EPS
7.07BMarket Cap
Oct 26Next Earn
Daan Gene Co., Ltd. Class A
SZSE:002030
(Shenzhen Stock Exchange)

Recent

price

5.37

P/E

ratio

- -

div

yld

0.12%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.26
0.32
0.42
0.6
0.77
1.05
1.17
1.12
1.05
0.78
3.81
5.46
8.58
0.79
0.61
0.54
0.54
Revenue per Share
0.04
0.05
0.07
0.1
0.11
0.07
0.08
0.06
0.07
0.07
1.75
2.58
3.86
0.07
-0.66
-0.53
-0.68
Basic EPS, GAAP
0.03
- -
-0.05
-0.03
-0.03
-0.11
-0.44
-0.3
0.21
- -
1.53
1.89
1.89
0.14
0.09
0.06
- -
Free Cash Flow per Basic Share
0.01
0.01
0.01
0.01
0.02
0.04
0.04
0.07
0.07
0.07
0.04
0.35
1.12
1.65
0.02
0.01
0.01
Dividend per Share
0.3
0.35
0.41
0.51
0.61
0.95
1.15
1.2
1.28
1.31
3.04
5.24
8.05
6.33
5.61
5.09
5
Book Value per Share
0.25
0.29
0.35
0.44
0.52
0.84
1
1
1.12
1.12
2.82
4.96
7.53
5.69
4.96
4.62
4.57
Tangible Book Value per Share
1,428
1,434
1,383
1,413
1,417
1,400
1,377
1,383
1,403
1,403
1,403
1,403
1,403
1,495
1,402
1,404
1,403
Basic Weighted Avg Shares
370
458
583
854
1,086
1,474
1,613
1,542
1,479
1,098
5,341
7,664
12,046
1,181
853
758
751
Sales/Revenue/Turnover
13.13
11.85
6.17
11.29
10.41
7.78
8.82
9.42
10.06
17.8
50.42
53.58
56.63
4.82
-26.88
-39.22
-34.34
Operating Margin (%)
31
34
36
35
46
56
64
76
88
76
72
192
298
357
350
300
- -
Depreciation Expense
56
68
90
144
153
101
107
86
102
92
2,449
3,618
5,412
105
-925
-744
-958
Net Income, GAAP
16.55
14.71
8.12
20.43
19.04
13.81
10.59
14.14
15.04
879.44
15.6
12.17
14.11
36.82
- -
- -
- -
Effective Tax Rate (%)
15.26
14.86
15.47
16.83
14.09
6.87
6.62
5.6
6.87
8.39
45.85
47.21
44.93
8.86
-108.46
-98.25
-127.54
Profit Margin (%)
212
208
218
350
402
1,218
1,736
1,616
703
636
2,262
3,464
5,800
3,589
2,488
1,836
1,806
Working Capital
- -
- -
- -
- -
- -
- -
200
325
50
290
47
66
67
22
13
3
3
LT Debt
482
554
626
767
915
1,940
2,553
2,642
2,163
2,087
4,515
7,660
11,616
9,157
8,143
7,365
7,241
Total Equity
6.51
7.19
10.58
15.64
13.11
3.99
2.9
2.51
2.49
-1.57
60.9
54.4
54.83
0.75
- -
- -
- -
Return on Invested Capital (%)
10.88
12.5
14.43
17.82
15.21
5.64
3.84
3.29
4.68
-4.02
61.3
55.88
54.44
1.35
- -
- -
- -
Return on Capital (%)
14.27
14.92
16.95
22.41
19.6
9.29
7.27
5.26
5.86
5.08
80.16
62.28
58.03
1.04
-11.04
-9.91
-12.82
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
111
127
105
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,403
1,403
1,403
Market Capitalization
8,365
8,294
7,073

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,844
2,800
2,726
Cash, Cash Equivalents & STI
1,100
1,102
1,137
Accounts Receivable, Net
746
719
697
Inventories
148
147
144
Total Current Liabilities
1,007
939
921
Payables & Accruals
- -
- -
- -
ST Debt
111
127
105
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.93%
15.9%
-9.56%
Free Cash Flow
-60,788.23%
-28.84%
-36.08%
Net Income, GAAP
154.72%
-200.85%
-19.54%
Sales/Revenue/Turnover
33.3%
-5.7%
-11.18%
Total Cash Common Dividend
88.3%
169.27%
-69.66%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
198
202
191
262
853
2025
169
169
- -
254
758
2026
149
178
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-0.03
-0.07
-0.3
-0.66
2025
0.04
-0.17
- -
-0.43
-0.53
2026
-0.07
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
- -
- -
0.02
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Daan Gene Co., Ltd. (002030.SZ) researches, develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables for molecular diagnostics, immunoassay, pathology, clinical chemistry, and point-of-care testing. The company offers fluorescence quantitative PCR series products for clinical applications including hepatitis viruses, sexually transmitted infections, blood screening, digestive pathogens, COVID-19, pharmacogenomics, human papillomavirus, human immunodeficiency virus, respiratory infections, tumor markers, and nucleic acid extraction; chemiluminescence and time-resolved immunoassay series; colloidal gold, biochemical, mass spectrometry, and POCT series products; polymerase chain reaction systems, sample preparation and nucleic acid extraction instruments; liquid-based cytology and pathology equipment; immunochromatography and microcolumn gel products; fluorescence in situ hybridization kits; sample collection kits; testing and scientific research services; instruments and software products under brands such as Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech. Founded in 1993 and headquartered in Guangzhou, China, Daan Gene operates primarily in domestic markets with products serving over 140 countries and regions, employing 1,730 staff as a leading provider in the in-vitro diagnostics industry. Recent developments include the launch of the CYP2C19 Genotyping Diagnostic Kit, Influenza A and B virus testing reagents, human MTHFR gene typing detection kit, and China's first nucleic acid detection kit for Chikungunya virus approved in Guangdong in 2025; authorization to management for selling up to 3% of shares; and plans by Guangzhou Pharmaceutical Group to acquire 233 million shares.